Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.23.2
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jul. 31, 2023
Jul. 31, 2022
Jul. 31, 2023
Jul. 31, 2022
Oct. 31, 2022
Segment Reporting Information [Line Items]          
Total $ (2,548) $ (2,775) $ (7,209) $ (10,242)  
Total operating costs and expenses 2,844 2,797 8,170 10,266  
Less non-cash share-based compensation (1,217) (1,446) (3,507) (5,546)  
Total 1,627 1,351 4,663 4,720  
Total 26,578   26,578   $ 30,412
Cart Therapeutics [Member]          
Segment Reporting Information [Line Items]          
Total (1,091) (965) (2,999) (3,975)  
Total 713 421 1,930 1,823  
Total 11,640   11,640   16,921
Cancer Vaccines [Member]          
Segment Reporting Information [Line Items]          
Total (1,390) (903) (3,261) (3,684)  
Total 855 376 1,966 1,571  
Total 13,968   13,968   9,442
Anti Viral Therapeutics [Member]          
Segment Reporting Information [Line Items]          
Total (62) (904) (960) (2,565)  
Total 55 552 572 1,312  
Total 898   898   3,811
Other [Member]          
Segment Reporting Information [Line Items]          
Total (5) (3) 11 (18)  
Total 4 $ 2 195 $ 14  
Total $ 72   $ 72   $ 238